To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Intercytex reforms as U.S: Department of Defense funds Vavelta scar therapy trials for injured soldiers
15-11-2010: Intercytex announced that it has reformed as a private enterprise and that its lead product, the cell therapy (VAVELTA®) will be evaluated by the US military to help treat injured soldiers.
Battlefield mortality has decreased from 30% in World War II to less than 10% in present day conflicts, partly as a result of better medical care. Sadly, this increased survival has been associated with a rise in the number of patients with chronic disabilities including burn and trauma scars. Burns account for approximately 10% of all combat casualties and Improvised Explosive Devices (IEDs), which are an increasingly common feature of today’s conflicts, are associated with extensive traumatic skin loss. As a result, burn and trauma scar contractures (where skin around the wound contracts, thickens and becomes inelastic) are a significant and growing problem for injured war heroes.
‘I am really delighted to announce the relaunch of Intercytex on Armistice Day since our lead product, VAVELTA® has the potential to make a real difference to the lives of injured troops’ commented Dr Kemp, Intercytex’s new Chief Executive Officer. ‘VAVELTA® has already been used in a small number of patients suffering from scar contractures and the outcome of these treatments has led to this Phase II trial in military personnel with burn scars. The work is funded by a significant agreement with the US Department of Defence and the clinical trial is scheduled to begin at Pittsburgh University Hospital, US, in 2011 in partnership with the McGowan Institute for Regenerative Medicine.’
VAVELTA® is a suspension of human dermal fibroblasts (HDFs, which are naturally derived skin cells and not modified in any way) in cell storage medium, for injection into the skin. The newly introduced HDFs are believed to lay down collagen and repair the extracellular matrix to improve skin structure and function.
Contact / Request information
Request further information free of charge:
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 7Sanofi-aventis to acquire Oenobiol
- 8Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 9DSM Sinochem Pharmaceuticals opens new 6-APA intermediate plant in China
- 10Pharmsynthez granted Orphan Drug Designation for Virexxa in the US
- History of analytical measuring technology in Jena
- Malvern Instruments announces global agreement with Proveris Scientific
- Analytik Jena to develop products for sepsis diagnostics
- analytica Vietnam 2013 – Platform for innovations
- Promega and BASF develop alternative method on identifying allergenic substances
- PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch
- PRAC recommends restricting the use of flupirtine-containing medicines
- Frost & Sullivan: BRIC is not delivering promises of high growth in healthcare markets
- New virus isolated from patients with severe brain infections
- PRAC recommends restricting the use of codeine when used for pain relief in children